Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2014 2
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Differential diagnosis of Huntington's disease: what the clinician should know.
Cardoso F. Cardoso F. Neurodegener Dis Manag. 2014;4(1):67-72. doi: 10.2217/nmt.13.78. Neurodegener Dis Manag. 2014. PMID: 24640980
Autosomal-dominant diseases that can mimic HD are HD-like 2, C9orf72 mutations, spinocerebellar ataxia type 2, spinocerebellar ataxia type 17 (HD-like 4), benign hereditary chorea, neuroferritinopathy (neurodegeneration with brain iron accumulation …
Autosomal-dominant diseases that can mimic HD are HD-like 2, C9orf72 mutations, spinocerebellar ataxia type 2, spinocerebellar ataxia type 1 …
Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases.
Painous C, van Os NJH, Delamarre A, Michailoviene I, Marti MJ, van de Warrenburg BP, Meissner WG, Utkus A, Reinhard C, Graessner H, Tijssen MA. Painous C, et al. Eur J Neurol. 2020 Aug;27(8):1493-1500. doi: 10.1111/ene.14302. Epub 2020 Jun 19. Eur J Neurol. 2020. PMID: 32386078 Free PMC article.
A survey about the management of different rare movement disorders (group 1, dystonia, paroxysmal dyskinesia and neurodegeneration with brain iron accumulation; group 2, ataxias and hereditary spastic paraparesis; group 3, atypical parkinsonism; group …
A survey about the management of different rare movement disorders (group 1, dystonia, paroxysmal dyskinesia and neurodegeneration wi …
The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.
Gassen M, Youdim MB. Gassen M, et al. Pharmacol Toxicol. 1997 Apr;80(4):159-66. doi: 10.1111/j.1600-0773.1997.tb00390.x. Pharmacol Toxicol. 1997. PMID: 9140134 Review.
Neurodegeneration is characterized by a marked accumulation of iron in the affected brain regions. ...Iron chelators, if they effectively prevent radical formation, have great therapeutic potential against ischaemia/reperfusion, rheumatoi …
Neurodegeneration is characterized by a marked accumulation of iron in the affected brain regions. ...Iron …
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up.
Cossu G, Abbruzzese G, Matta G, Murgia D, Melis M, Ricchi V, Galanello R, Barella S, Origa R, Balocco M, Pelosin E, Marchese R, Ruffinengo U, Forni GL. Cossu G, et al. Parkinsonism Relat Disord. 2014 Jun;20(6):651-4. doi: 10.1016/j.parkreldis.2014.03.002. Epub 2014 Mar 12. Parkinsonism Relat Disord. 2014. PMID: 24661465
In the same subjects MRI evaluation showed reduced hypointensity in the globus pallidus (GP); quantitative assessment confirmed a significant increment in the T2* value, and hence reduction of the iron content of the GP. CONCLUSION: The data from our 4-years follow- …
In the same subjects MRI evaluation showed reduced hypointensity in the globus pallidus (GP); quantitative assessment confirmed a significan …